title: [Neck dissection following chemoradiation for node positive head and neck carcinomas].
abstract: The optimal timing and extent of neck dissection in the context of chemoradiation for head and neck cancer remains controversial. For some institutions, it is uncertain whether neck dissection should still be performed upfront especially for cystic nodes. For others, neck dissection can be performed after chemoradiation and can be omitted for N1 disease as long as a complete response to chemoradiation is obtained. The question is debated for N2 and N3 disease even after a complete response as the correlation between radiological and clinical assessment and pathology may not be reliable. Response rates are greater than or equal to 60% and isolated neck failures are less than or equal to 10% with current chemoradiation protocols. Some therefore consider that systematic upfront or planned neck dissection would lead to greater than or equal to 50% unnecessary neck dissections for N2-N3 disease. Positron-emission tomography (PET) scanning to assess treatment response and have shown a very high negative predictive value of greater than or equal to 95% when using a standard uptake value of 3 for patients with a negative PET at four months after the completion of therapy. These data may support the practice of observing PET-negative necks. More evidence-based data are awaited to assess the need for neck dissection on PET. Selective neck dissection based on radiological assessment and peroperative findings and not exclusively on initial nodal stage may help to limit morbidity and to improve the quality of life without increasing the risk of neck failure. Adjuvant regional radiation boosts might be discussed on an individual basis for aggressive residual nodal disease with extracapsular spread and uncertain margins but evidence is missing. Medical treatments aiming at reducing the metastatic risk especially for N3 disease are to be evaluated.
authors.affiliation: Département de radiothérapie, oncologie, centre de lutte contre le cancer Antoine-Lacassagne, 33 avenue Valombrose, Nice cedex 2, France. jthariat@hotmail.com
authors.forename: J
authors.initials: J
authors.lastname: Thariat
authors.forename: M
authors.initials: M
authors.lastname: Hamoir
authors.forename: F
authors.initials: F
authors.lastname: Janot
authors.forename: E
authors.initials: E
authors.lastname: De Mones
authors.forename: P-Y
authors.initials: PY
authors.lastname: Marcy
authors.forename: P
authors.initials: P
authors.lastname: Carrier
authors.forename: A
authors.initials: A
authors.lastname: Bozec
authors.forename: N
authors.initials: N
authors.lastname: Guevara
authors.forename: S
authors.initials: S
authors.lastname: Albert
authors.forename: P-O
authors.initials: PO
authors.lastname: Vedrine
authors.forename: P
authors.initials: P
authors.lastname: Graff
authors.forename: F
authors.initials: F
authors.lastname: Peyrade
authors.forename: P
authors.initials: P
authors.lastname: Hofman
authors.forename: J
authors.initials: J
authors.lastname: Santini
authors.forename: J
authors.initials: J
authors.lastname: Bourhis
authors.forename: M
authors.initials: M
authors.lastname: Lapeyre
mesh_terms: D017024:Chemotherapy, Adjuvant; D006258:Head and Neck Neoplasms / Q000000981:diagnostic imaging / Q000473:pathology / Q000628:therapy*; D006801:Humans; D008207:Lymphatic Metastasis; D037981:Neck Dissection; D049268:Positron-Emission Tomography; D011379:Prognosis; D018714:Radiotherapy, Adjuvant